Where Will CRISPR Therapeutics Be in 5 Years?
Genetic medicines are beginning to make their way to market after decades of promise. The first gene therapy drug was approved in 2017, while the first drug based on RNA interference (RNAi) was approved in 2018. Next up: CRISPR gene editing.
Or that's what investors are hoping for, anyway. The potential of CRISPR gene editing has lifted CRISPR Therapeutics (NASDAQ: CRSP) to a market cap of $2.7 billion, even though its first drug candidate only entered clinical trials months ago. Despite that, the business does appear to have the best strategy among peers. It also has the largest pile of cash. While that doesn't guarantee success, it bodes well for the next five years. Here's what could happen in that time.
Image Source: Getty Images
Quelle Fool.com
